ENDIA

The Australian Therapeutic Goods Administration (TGA) has approved Tzield (teplizumab) to delay the onset of stage 3 (symptomatic) .

Stage 2 means two or more islet autoantibodies (early markers) have been detected from a blood test and glucose levels are erratic ( ), but no symptoms are evident.

The progression of type 1 diabetes happens in stages. People with stage 2 T1D will gradually progress to stage 3 T1D, with the experience of symptoms ( , , and losing weight, more often). Elevated glucose levels require insulin treatment. This process can take place over months or years.

Studies of Tzield have proven to slow this progression by an average of 2 years. That's at least two years less of injections and finger pricks.

This is the first new therapy approved for T1D in over 100 years, since the discovery of .

Tzield involves an intravenous (IV) infusion. People must be aged 8 years or older and in stage 2 type 1 diabetes.

Read more on the Breakthrough T1D Australia website:

https://breakthrought1d.org.au/news/tzield-approved-in-australia/

🌟 24 visits and 10 amazing years with Miss Addison!

This has completed her study visits with the ENDIA study cohort. That is an incredible commitment from Addison and her wonderful family, and we could not be more grateful. 💙

From her very first visit as a tiny baby to the amazing 10-year-old she is today, Addison has grown up as part of the ENDIA family — and what a journey it has been!

Every visit, every sample, and every moment of time her family has given is helping researchers better understand and how we might one day prevent it. What a truly remarkable gift to science and to future generations.

Thank you, Addison, and thank you to your family for your incredible dedication. You are the reason this research is possible. 🎉 And congratulations on reaching your first decade! Happy birthday.

Happy International Nurses Day to our valued ENDIA Nurses and all those fabulous nurses who have helped contribute to the ENDIA Study!

www.endia.org.au